Note: After the Food and Drug Administration (FDA) approves a medication, it tracks and reviews side effects of the drug. If you develop a side effect while using Dupixent and would like to inform ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Dupixent continues to be a transformative medicine ... an additional share repurchase authorization. I'll conclude with a review of our 2025 financial guidance. We expect 2025 R&D spend to be ...

The EMA has started a review of Leo Pharma’s interleukin-13 ... a category that is currently dominated by Sanofi and Regeneron’s Dupixent. The EU regulator is reviewing tralokinumab for ...

Dupixent becomes the first-ever targeted therapy ... The drug is also under review for this use in China, Japan, and other countries worldwide. Sanofi and Regeneron estimate that there are around ...

Obviously, Dupixent in COPD has a broader label ... Of course, any decision is subject to regulatory final active review. And then with respect to the label and monitoring, I think you'll see ...

Dupixent’s sales rose 16% year over year ... The FDA granted priority review to a supplemental new drug application (sNDA) seeking approval for Merck’s oral HIF-2α inhibitor, Welireg for ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...